The half-inhibition concentration (IC 50 ) of a drug indicates its ability to inhibit the binding of other ligands of a receptor. The authors used positron emission tomography to test the hypothesis that haloperidol's IC 50 toward the binding of tracer N-[
Previous studies (Wong et al., 1986c , Dewey et al., 1991 Laruelle et al., 1996) have claimed an effect of endogenous dopamine on the binding of neuroleptics and analogous radioligands to D 2 -like receptors in primate (human and monkey). Recently, Abi-Dargham et al. (2000) reported findings suggestive of increased dopamine concentration in brain of patients with schizophrenia, compared with healthy volunteers. When increased baseline dopamine concentration is associated with increased dopamine binding to receptors, it must raise the half-inhibition concentration of exogenous antagonists of this binding. The authors tested this prediction by comparing measures of the half-inhibition concentration of haloperidol in healthy volunteers and in volunteers with psychosis.
To test the prediction, the authors derived a theoretical basis for the in vivo determination of the half-inhibition constant of an exogenously supplied inhibitor. To specifically test the hypothesis that the apparent affinity to haloperidol must decline in states of psychosis in which the competition from dopamine is increased, the authors determined the apparent affinity for this neuroleptic in previously examined healthy volunteers, volunteers with bipolar disease with or without psychosis, and volunteers with schizophrenia (Wong et al., 1997b) .
The results are consistent with an elevation of the concentration of dopamine in patients with psychosis, whether from schizophrenia or bipolar illness, but decline of plasma protein binding or intrinsic receptor affinity for haloperidol also explain this finding.
MATERIALS AND METHODS

Operational equation
In the Appendix, the operational equation is derived, which was used to determine the half-inhibition plasma concentration of an unlabeled neuroreceptor antagonist by means of a tracer radioligand. The in vivo estimation of the half-inhibition concentration (IC 50 ) of an inhibitor of specific neuroreceptors requires (at least) two measurements of the rate or degree of binding of the radioligand, for example, in the presence and absence of the inhibitor Gjedde and Wong, 1990a,b) . The authors used the radioligand 3-N- [ 11 C] methylspiperone ([ 11 C]NMSP) to determine tho degree of dopamine D 2 -like receptor occupancy of the neuroleptic haloperidol in caudate nucleus, the dopamine D 2 -like receptors being the only significant neuroreceptors shared by [ 11 C]NMSP and haloperidol (Wong et al., 1986b) . The following six equations were derived in the Appendix and used to interpret the experimental results. They are listed here to show how estimates of the quantities of endogenous ligand and competitor can be made from the binding rate constant (k 3 ) or time constant ( ‫ס‬ 1/ k 3 ).
The assumptions underlying the equations include the claims that haloperidol and [
11 C]NMSP bind to the same binding site with single affinities, no change of the maximum binding capacity B max occurs between the two administrations of the tracer, no average differences of haloperidol free fractions in plasma and brain tissue exist between the groups of subjects, the true aqueous receptor affinity for haloperidol in vivo (K I ) can be known (although it may not be known correctly) and is the same for all groups and both injections, haloperidol is in steady state, the plasma aqueous-free haloperidol concentrations equal the synaptic aqueous-free haloperidol concentrations, no differences of free fractions exist between the groups, and the binding of [ 11 C]NMSP is unidirectional (that is, the dissociation constant k off is effectively nil) in all groups and at both injections. The effect(s) of departures from these assumptions are examined in the Appendix.
The operational equation relates the plasma IC 50 of haloperidol to the binding time constant of the tracer,
where K IC50(pl) symbolizes the plasma IC 50 , C I(pl) symbolizes the steady-state plasma concentration of haloperidol, and symbolizes the time constant of unidirectional binding of the tracer [ 11 C]NMSP, equal to the reciprocal of the binding rate constant (1/k 3 ) in the absence () and presence ((I)) of the exogenous inhibitor. The symbol in parentheses, I, refers to the presence of the exogenous inhibitor haloperidol, that is, at the second tomography session, 4 hours after the oral administration of haloperidol. To calculate K IC50(pl) , the authors measured the plasma concentration of the inhibitor and the binding time constants of the tracer. With this value, the authors estimated the concentrations and occupancies of hypothetical endogenous competitors.
Equations of inference
To evaluate the influence of changes of the half-inhibition concentration of the inhibitor, five additional equations were derived, which allowed the authors to make inferences about several factors that affect the interpretation of the results of the study. These equations include:
1. The equation relating the concentration of one or more postulated endogenous competitors to the binding of haloperidol, the concentration expressed relative to the competitors' unknown Michaelis half-inhibition concentrations,
where x is the sum of the putative endogenous competitors, relative to their half-saturation constants, ⌺C x /K x , and where f I(pl) is the plasma "free" fraction of haloperidol at steady state. K I is the aqueous half-inhibition concentration of haloperidol in the absence of other inhibitors of the binding, that is, in the absence of the putative endogenous inhibitors.
Calculation of x requires that K IC50(pl) is known from Eq. 1 and that the free fraction of the inhibitor and the aqueous half-inhibition concentration of the inhibitor is known from the literature or measured separately in plasma. 2. The equation for the occupancy achieved by the putative endogenous competitor(s) in the absence of the exogenous antagonist,
where x (0) is the occupancy at the receptors achieved by the putative endogenous competitor(s) in the absence of exogenous inhibition. The calculation of x (0) required that x is known from Eq. 2. 3. The equation relating the concentration of the exogenous inhibitor relative to its inhibitory constant to the binding time constants and the sum of the relative concentrations of other competitors,
where I is the concentration of the exogenous inhibitor relative to its inhibitory constant. The calculation of I requires that x is known from Eq. 2. 4. The equation for the occupancy achieved by the exogenous antagonist in the presence of the endogenous competitor(s),
where I (x)is the occupancy achieved by the exogenous inhibitor in the presence of the endogenous competitor(s). The calculation of I (x) requires that x is known from Eq. 2 and that I is known from Eq. 4. 5. The equation for the occupancy achieved by the putative endogenous competitor(s) in the presence of the exogenous antagonist,
where x (I)is the occupancy achieved by the putative endogenous competitor(s) after the blockade of the receptors by the exogenous inhibitor. The calculation of x (I) requires that x is known from Eq. 2 and that I is known from Eq. 4.
These equations were derived in the Appendix for a radioligand that binds unidirectionally to the neuroreceptors during the time available for positron emission tomography. In addition, in the Appendix, the criteria are established that must be fulfilled for the authors to claim that binding of the radioligand was in fact unidirectional for the duration of the positron emission tomography.
Volunteers
All healthy subjects and patients volunteered and gave their informed consent to the study, in compliance with the Johns Hopkins Committee on Clinical Investigation. The details of the volunteers participating in this study were presented previously (Wong et al., 1986a (Wong et al., ,c, 1997b . The distribution of the subjects between the years 1986 and 1997 is listed in Table 1 .
Briefly, 14 patients with bipolar affective disorder (7 men and 7 women, mean age ‫ס‬ 43 years), 22 drug-naive patients with schizophrenia (17 men and 5 women, mean age ‫ס‬ 36 years), 5 drug-free but previously medicated patients with schizophrenia (mean age ‫ס‬ 27 years), and 22 healthy volunteers (17 men and 5 women, mean age ‫ס‬ 33 years) were recruited. Of the patients with bipolar disease, 11 were drugnaive and 3 drug-free for at least 2 months. Of the patients with
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bipolar disease, 3 were depressed and 11 were manic at the time of study. On the basis of DSM-III, -IIIR, and -IV criteria as described in Wong et al. (1986a Wong et al. ( ,c, 1997b , the patients with bipolar disease were divided in two groups-patients without episodes of psychosis and patients with episodes of psychosis during the tomography. Subjects were divided categorically into those who were psychotic by definition at all times for the drug naive schizophrenic patients or specifically at the time of scanning for the psychotic bipolar patients, in contrast with the nonpsychotic bipolar patients. In patients with bipolar disease, the episodic nature necessary required the identification of active hallucinations and delusions during the positron emission tomography scan time. Patients with bipolar illness who exhibited active hallucinations and delusions were considered psychotic, whereas those that did not present with these symptoms were considered nonpsychotic. Patients and healthy volunteers did not differ significantly with respect to blood pressure, pulse, weight, and nutritional status at the time of study. Further clinical details were given by Tune et al. (1993) and Pearlson et al. (1993 Pearlson et al. ( , 1995 .
Tomography
The tomography is described in details in previous articles by Wong et al. (1986c Wong et al. ( , 1997a . Briefly, in each patient, the binding time constant of N-[
11 C]methylspiperone, labeled according to Burns et al. (1984) to the high specific activity of 2 mCi pmol −1 , was measured twice by positron emission tomography after 10-to 20-second injection of 20 mCi into an antecubital vein. The injected mass averaged 30 pmol (kg body weight) −1 . The specific activities did not differ between the injections.
Each tomography session lasted 90 minutes. Emitted radioactivity was recorded with the NeuroECAT tomograph (CTI; Knoxville) in its highest resolution mode. Radioactivity was simultaneously detected in caudate nucleus and cerebellum in 5 frames of 2 minutes, 5 frames of 5 minutes, and single frames of 15 and 30 minutes each. Between the 2 tomography sessions, 4 hours before the second session, all subjects ingested 300 to 400 nmol kg −1 haloperidol resulting in steady-state plasma concentrations that averaged less than 10 nmol/L in subjects without psychotic episodes and more than 10 nmol/L in subjects with such episodes.
Blood samples for radioactivity and haloperidol concentration measurements were obtained from the dorsal vein of the hand contralateral to the injection hand, after "arterialization" by heating to 44°C, and, in some cases, from the radial artery. The sampling schedule consisted of 4 to 6 samples the first minute after the tracer injection, 3 to 6 samples the second minute, 2 samples the third and every subsequent minute until the tenth minute, and samples at 25, 30, 45, 60, 75, and 90 minutes. Blood samples were centrifuged and samples of the plasma were counted in a gamma-scintillation spectrometer. In previous comparisons, results obtained with arterialized venous sampling did not differ significantly from results obtained with arterial sampling (Wong et al., 1997a) .
Quantitative analysis
Quantitative analysis of the studies was performed by an investigator blinded to the clinical diagnosis, as described by Wong et al. (1986a,b,c) . Calculations of IC 50 and x were made from values of the time constants of unidirectional binding of tracer [
11 C]NMSP in the caudate nucleus in the absence and presence of haloperidol in all subject groups, according to Eqs. 1 and 2. Analysis of variance detected the significant differences among the patient groups.
Time constants ( ‫ס‬ 1/ k 3 ) of unidirectional binding of tracer [ 11 C]NMSP were directly estimated from the time-radioactivity curves in brain tissue, as described by . Plasma haloperidol concentrations were determined as described by Wong et al. (1997b) and the grand average of the measurements was used as listed in Table 2 . The average free fractions [ƒ I(pl) , mean ± SD (n)] for [
18 F]haloperidol of the individual groups were 0.035 ± 0.002 (10) for schizophrenia, 0.041 ± 0.008 (5) for bipolar illness, and 0.033 ± 0.005 (7) for controls.
Putative endogenous competitor concentration ratios were computed from Eq. 2, using the value of the haloperidol "free" plasma fraction (ƒ I(pl) ) of 0.033 reported by Wong et al. (1997a) , and an aqueous haloperidol half-inhibition concentration of 0.043 nmol/L in the absence of endogenous or other exogenous inhibitors, as reported by Ishizu et al. (2000) for the pig and listed in Table 2 .
Equations 3 to 6 were used to predict the degrees of receptor occupancy established by the putative endogenous competition and exogenous inhibition and the actual neurotransmitter binding to the receptors in the groups of volunteers.
RESULTS
The authors confirmed the unidirectionality of [ 11 C]NMSP uptake into the caudate nucleus by modeling the uptake with and without dissociation from the receptors at the rate reported by Logan et al. (1987) and listed in Table 2 . The plasma free fraction of haloperidol listed 
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in Table 2 was measured in the second group of subjects added to the Wong et al. (1986c) group by Wong et al. (1997a) . The K I of haloperidol in aqueous solution (listed in Table 2 ) was calculated from studies of people by Logan et al. (1987) and pigs by Ishizu et al. (2000) .
The [ 11 C]NMSP dissociation rate constant k 4 of 0.003 min −1 (0.18 h −1 ) was not sufficient to render the binding less than approximately unidirectional during the 90-minute tomography, assuming unlimited specific activity of the tracer. In the 90 minutes, the accumulation was 95% of the accumulation expected with complete unidirectionality. In terms of the total amounts of radioligand, the authors estimated that the s/ ratio (Appendix, Eqs. 12 and 14) never exceeded 0.05 during the 90 minutes and that the transfer therefore must be effectively unidirectional, even if the inclusion of dissociation would yield different estimates of the magnitude of . Therefore, the authors limited the regression for to three parameters.
In agreement with the previous analysis (Wong et al., 1997b) , the average estimates of the magnitude of did not differ among the groups, except for the nonpsychotic patients with bipolar disease. Plasma haloperidol concentrations did not vary significantly among the subject groups, although the concentration averages were twice as high in the psychotic patients, as shown in Table 3 . This variation is well known from the literature (Midha et al., 1989; Goff et al., 1991) but remains unexplained. When the measurements were lumped according to the patients' condition at the positron emission tomography measurement (nonpsychotic or psychotic), the plasma haloperidol concentrations were significantly elevated in the psychotic subjects. The average neuroleptic blockade corresponded to group mean haloperidol occupancies of 70% to 87%.
The values of the haloperidol IC 50 (K IC50(pl) ) were calculated from Eq. 1 as normally distributed, because denominator values generally were large rather than small. Averages differed significantly among the five groups (F ‫ס‬ 2.81, P ‫ס‬ 0.05). The apparent affinity was significantly decreased in the drug-naive patients with schizophrenia, compared with healthy volunteers (t ‫ס‬ 2.84, P ‫ס‬ 0.008). Multiple regression against age showed a significant relation between the IC 50 and age in the patients with bipolar disease who had had psychotic
No other group showed a significant change of IC 50 with age, the values deviating insignificantly from the 1.5 nmol/L average for healthy volunteers and patients with bipolar disease without episodes of psychosis, and 4.5 nmol/L for patients with schizophrenia or psychosis of other origin.
DISCUSSION
In 1986, the authors reported that therapeutic doses of haloperidol block 70% to 90% of the dopamine receptors imaged by [ 11 C]NMSP (Wong et al.,1986b ), but they also found that the IC 50 of haloperidol was higher in patients suffering from psychosis than in subjects not so afflicted (Wong et al.,1986c) . Hence, the results of these experiments do not reject the hypothesis that patients with psychosis have a higher endogenous neurotransmitter binding to dopamine receptors than subjects without psychosis (Abi-Dargham et al., 2000) . Nonetheless, numerous assumptions underlie the equations used, and multiple factors influence the results. Increased endogenous neurotransmitter level is only one among a multitude of possible interpretations of the data. A theoretical description of some of the many possible interpretations is given in the Appendix.
Increased intrasynaptic dopamine has been hypothesized since the earliest formulation of the dopamine theory of schizophrenia. Early evidence originated from an in vivo study of the binding of [ 11 C]NMSP in ventral striatum and nucleus accumbens in schizophrenia (Wong et al., 1986c ). Using the procedure described here, the authors noted an apparent increase of the haloperidol affinity constant in the patients, which was interpreted as a possible increase of endogenous dopamine (footnote 16, Wong et al., 1986c ). In the current study, the authors extend the calculation to include bipolar illness and provide a theoretical basis for the interpretation of the results in terms of dopamine binding, as shown in Table 4 .
For the purpose of inference about dopamine binding, the group averages were lumped into the three classes listed in Table 4 . The class averages formed the basis of speculations on the quantities of free and bound neurotransmitter and antagonist, incorporating previously published estimates of the maximum binding capacities 
Healthy Control (22) I 7.1 ± 0.6 22 ± 3 116 ± 18 1.7 ± 0.5 Bipolar illness Nonpsychotic (7) II 7.6 ± 1.8 14 ± 1 104 ± 9 1.0 ± 0.2 Psychotic (7) III 13.3 ± 3.9 32 ± 4 105 ± 13 5.8 ± 3.7 Schizophrenia Drug-naive (22) IV 15.3 ± 3.7 24 ± 4 117 ± 21 4.0 ± 0.6 Drug-free (5) V 26.1 ± 16.2 20 ± 9 136 ± 62 4.6 ± 0.9
Means are ±SEM for comparison among groups.
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(B max ) of the three subject classes (Wong et al., 1997b) . Using the same value of the plasma "free" fraction f I(pl) for all groups, and the aqueous half-inhibition concentration K I of 0.043 nmol/L for haloperidol listed in Table  2 , the total relative concentration of putative endogenous competitors averaged 0.15 in the nonpsychotic or healthy subjects, corresponding to an average receptor occupancy of 13%. The quantity of bound endogenous competitors was estimated to be 2.5 pmol cm −3 at a total [ 11 C]NMSP receptor density of 19 pmol cm −3 at age 40. In the psychotic patients with bipolar disease or drugnaive schizophrenic patients, the total relative concentration of putative endogenous competitors averaged 2.45, a 16-fold increase, corresponding to an 8-fold increase of receptor occupancy (71%, or 21 pmol cm −3 of a total [ 11 C]NMSP receptor density of 29 pmol cm −3 at age 40). After haloperidol blockade, the putative endogenous competitor occupancy declined to 2.2% in the combined groups I and II and to 16% in the combined groups III and IV (0.4 pmol cm −3 and 4.7 pmol cm −3 , respectively), as shown in Table 3 . Thus, even at the higher plasma haloperidol concentration, patients in groups III and IV had a lower haloperidol occupancy and a 12-fold higher putative endogenous neurotransmitter binding than the subjects in groups I and II.
Notably, the predicted residual neurotransmitter binding in the haloperidol-blocked patients in groups III and IV was only twice as high as the predicted neurotransmitter binding in the volunteers in groups I and II (those without psychosis). These results show that the haloperidol blockade tended to normalize the neurotransmitter binding in the patients with psychosis.
The analysis predicted that patients with schizophrenia who had received neuroleptics previously did not have a higher neurotransmitter binding than did the patients who never received medication (4 vs. 4.7 pmol cm −3 ). Thus, the plasma haloperidol concentration was not elevated by greatly increased agonist competition at the receptor sites, as the bound endogenous competitors differed little between the two groups ( x 2.53 vs. 2.45).
The theoretical treatment (Appendix) revealed that estimates of the apparent affinity of an administered receptor antagonist can be used to infer changes of neurotransmitter concentration in brain only on certain conditions. This means that the significant elevation of the haloperidol plasma IC 50 in patients with psychotic potential has other possible explanations. In the Appendix, an expression for K IC50(pl) (Eq. 47) is derived that identifies several factors that could have contributed to the measured increase,
including the free plasma fraction of the inhibitor (f I(pl) ), the intrinsic affinity constant of the inhibitor itself (K I ), the possible endogenous nonagonist competitors ( i ), the endogenous agonists ( a ), the G-protein-induced affinity change of the agonists (⌫), and the inhibitor-induced relative increase of the endogenous agonists ().
The claim that the level of endogenous competition of the haloperidol binding (exerted by i , or a , or both) is elevated in the patients assumes that neither the inhibitor's plasma "free" fraction nor the intrinsic affinity of its receptors has changed. The current calculation used the same plasma "free" fraction of haloperidol in all the subject groups. As previously discussed by Wong et al. (1997b) , it is unlikely that the change of the IC 50 arose because of different degrees of protein binding.
The calculation assumes that haloperidol binds competitively to the receptors, which also bind NMSP, and that the inhibition in theory can reach 100%. Although the group mean occupancies averaged 70% to 87%, the calculated occupancy reached 100% in some subjects. Lyon et al. (1986) and Frost et al. (1987) recorded near-100% occupancies of NMSP receptors in rodents, and Ishizu et al. (2000) showed that haloperidol bound C I(pl) is the concentration of the exogenous inhibitor in arterial plasma. K IC50(pl) is the apparent half-inhibition concentration of the inhibitor in arterial plasma. x is the sum of putative endogenous competitors, relative to their half-saturation concentrations. B max (40) is the maximum binding capacity in ventral caudate nucleus at age 40 reported by Wong et al. (1997b) . x (0) is the occupancy of the endogenous competitor(s) in the absence of exogenous inhibition. B x(40) is the predicted binding of neurotransmitter x at age 40. I is the concentration of exogenous inhibitor, relative to its inhibitory constant. I (x) is the occupancy of the exogenous inhibitor in the presence of the endogenous competitor(s). x (I) is the occupancy of the putative endogenous competitor(s) in the presence of the exogenous inhibitor. B x (1)(40) is the predicted binding of neurotransmitter x after neuroleptic blockade at age 40. Remaining symbols are defined in relation to the equations indicated in the table.
A. GJEDDE AND D. F. WONG 986
competitively over a range of multiple concentrations, although no concentration reached as high as recorded in some patients in this study.
The calculation also assumes a single value for the intrinsic haloperidol half-inhibition concentration (K I ), but there is no direct evidence that the affinities of the relevant neuroreceptors for haloperidol in fact remain unchanged. For this reason, it can not be ruled out that a fundamental change of the receptors occurred in patients with the psychotic potential that caused the inherent affinity toward haloperidol to decline. In the final analysis, however, it is difficult to distinguish between an intrinsic decline of affinity and a decline imposed by the elevation of a competitor, because it is not known how the affinity of dopamine receptors is regulated.
The interpretation that the level of endogenous competitors of the haloperidol binding is elevated in the patients is consistent with previous claims that extracellular dopamine levels may be high in patients with active psychosis, or that the administration of a neuroleptic leads to greater extracellular release of dopamine in patients with psychotic tendencies than in patients without these tendencies.
Rather than making distinctions among the different roles of nonagonists, agonists, and G-proteins, the current analysis yielded a single estimate of the "lumped" baseline endogenous competitor concentration relative to its affinity constant ( x ). In Eq. 7, the apparent concentration of this "lumped" competitor, relative to a weighted affinity, is
according to which the calculated increase is an estimate of an extracellular dopamine elevation only when the level of other competitors and G-protein action remain unchanged and when the inhibitor itself induces no change of dopamine or G-protein action. Thus, it was not possible to give a direct estimate of the absolute agonist concentration because the apparent affinities of partial and complete agonists probably do change as functions of the agonist concentration itself. Independently of changes of membrane potential, dopamine action at the D 2 , D 3 , and D 4 receptors in the striatum is mediated primarily by G o proteins that form ternary complexes with the agonist-activated receptor (Wang et al., 1995; Beindl et al., 1996; ). The striatal D 2 receptor is predominantly of the D 2L "long" isoform in which the long third cytoplasmic loop mediates coupling to the G-proteins (Guivarc'h et al., 1995) . As derived in the Appendix, this coupling leads to an increase of the apparent affinity of the receptor to the agonist, which contributes to an increase of K IC50(pl) . Laruelle et al. (1996 Laruelle et al. ( , 1997 reported a decline of the binding potential of a labeled benzamide tracer induced by administration of amphetamine to healthy volunteers and patients with schizophrenia. The decline of the binding potential was inferred from calculations of the ratio of specific-to-nonspecific binding of the tracer that would not reveal the baseline concentration of the endogenous neurotransmitter, as argued above, but would reveal the transient change induced by the administered amphetamine. In schizophrenic patients, the decline was significantly more pronounced than in the healthy control subjects. On the basis of this finding, Laruelle et al. (1997) claimed that the release of an endogenous competitor of the tracer binding was more pronounced in schizophrenia. Equation 7 shows that not only the release of the agonist but also a G-protein-induced increase of the agonist's affinity could explain the finding.
Amphetamine is not the only agent capable of releasing dopamine to the extracellular space; both haloperidol and raclopride are neuroleptics known to have this effect (Westerink and de Vries, 1989) . Equation 7 shows that it is possible to miss increases of receptor density and halfinhibition concentration if pathologically elevated but transient increases of the endogenous competitor occur as a consequence of the administration of the exogenous inhibitor, as has been shown for schizophrenia. This is also possible when the exogenous inhibitor is itself a tracer administered at low specific activity, as is the case when raclopride is used as a tracer of dopamine D 2 -like receptor density (Farde et al., 1990 (Farde et al., , 1995 . In the current experimental design, the authors were not in a position to ascertain whether any such "hidden" agonist increase persisted long enough after the administration of the exogenous antagonist to affect the estimates reported. However, if the estimates were affected, it would lower rather than further increase the estimates of the Michaelis constants. Thus, a "hidden" agonist surge would render the current estimates of the IC 50 of haloperidol too low.
Recently, Abi-Dargham et al. (2000) attempted to measure the baseline endogenous competitor level by increasing the binding of an exogenous competitor with drugs that deplete the dopamine (for example, AMPT). The outcome of this study was interpreted as showing a greater baseline dopamine level in patients with schizophrenia than in healthy volunteers. As such, that study agrees with the conclusions drawn from the current study, although the change calculated by Abi-Dargham et al. (2000) is much smaller than determined in the current study.
On the basis of the observations reported here, the authors speculate that the propensity for psychosis is associated with increased endogenous neurotransmitter binding to dopamine D 2 -like receptors in the most ventral parts of the caudate nucleus. Variations of the baseline level of endogenous competition may invalidate
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measures of binding rate or potential as index of receptor density (Wolf et al., 1996) , and transiently increased endogenous competition, as a result of exogenous inhibitor administration, may mask changes of receptor density, or Michaelis half-saturation concentration, or both (Farde et al., 1990 (Farde et al., , 1995 . Dopamine-induced inhibition of haloperidol binding speaks against the 'denervation hypersensitivity' theory of low extracellular dopamine as the explanation of episodes of psychosis in these disorders, unless it is also argued that the extracellular dopamine is lowered outside the synapses and elevated in the synaptic cleft. Such a differential change would represent a shift of dopamine from a more static pool outside vesicles and synapses to the more dynamic pool in the vesicles and the synapses.
The apparent ('measurable') affinity of the D 2 -like receptors to dopamine in the high-affinity state is 10-fold greater than the affinity of the D1-like receptors, approximately 1 nmol/L versus 10 nmol/L Van Tol, 1993, 1994) . The intrinsic affinity is unknown. Speculating on the basis of the G-protein effect discussed above that the intrinsic affinity is no more than 1% of the apparent agonist-induced affinity (that is, that K a is no less than 100 nmol/L), the intrasynaptic dopamine concentration is Ն15 nmol/L in the healthy volunteers studied here, and 10-fold greater in the individuals with psychosis. This speculation about the concentration of dopamine on the basis of occupancy figures must take into account agonist-induced affinity changes. 
APPENDIX
Unidirectional binding
The criteria of unidirectional binding are inherent in the conventional binding equation of which the Michaelis-Menten equation is the equilibrium solution. The claim of unidirectionality is essential to current use of the Woolf-Hanes Plot. This Appendix derives the theoretical criterion of unidirectionality that allowed the authors to make the claim on the basis of known rate constants of the brain uptake of the radioligand used in this study. The binding equation is the differential equation expressing the simplest current understanding of the competitive interaction between a radioligand and its neuroreceptors, 
where m e is the mass of all nonspecifically bound or unbound ligand in the tissue, V d represents the volume of no-affinity and low-affinity (that is, transiently equilibrating with immeasurable rapidity) distribution of the ligand in the tissue, equal to the ratio m e /c, and K D is the Michaelis or half-saturation concentration constant of the ligand, equal to the ratio between the magnitudes of k d and k a (in the absence of internalization or other transport of the bound ligand). When the magnitude of the variable c is either negligible compared with the magnitude of the constant K D or actually constant, b defines a single kinetic compartment.
When the rate constant of uninhibited unidirectional binding, k 3 , is defined as the term k a B max /V d in Eq. 10, the equation rearranges to,
ͪͬ (11) where the ratio b/B max is the time-variable fractional saturation (s) of the receptors by the radioligand, and the ratio c/(c + K D ) is the equilibrium fraction of occupancy of the receptors (), that is, the occupancy theoretically achievable at the radioligand concentration c. When these symbols are introduced into Eq. 11,
it is evident that binding equilibrium exists when the s/ ratio is unity. Because the magnitudes of s and by definition are equal at equilibrium, the unidirectional rate of binding can not be measured although it may be more or less substantial, depending on the magnitude of k 3 . The ratio between s and indicates the degree to which the binding is unidirectional within a given period of time.
When the magnitude of c is negligible compared with K D (that is, when the specific activity of the radioligand is infinitely high, as assumed in the current experiments), the halftime of approach to equilibrium, and hence the unidirectionality of the binding, depend on the magnitude of the dissociation constant k d . The reciprocal of k d is the time constant of dissociation. For times sufficiently short relative to the magnitude of the time constant of dissociation, s << and s/ is practically nil. Thus, the measured rate of binding is approximately unidirectional when,
which is the same as stating that the binding is unidirectional when,
where m is the total amount of tracer in the tissue, and mЈ e is the quantity of unbound tracer remaining in the absence of dissociation of bound tracer from the receptors. In practical terms, according to Eq. 14, this requirement is upheld when the entire radioactivity actually in the tissue is not much less than the quantity predicted in the absence of significant loss from the brain of previously bound tracer. Thus, what matters is not whether tracer dissociates from the binding compartment, but whether any previously bound tracer is lost from the tissue as a whole and not registered by the scanning.
Woolf-Wong-Hanes plot of inhibition
It was necessary to establish the influence of one or more competitors on the time constant of unidirectional binding. The authors based the kinetics on the del Castillo-Katz-Lefkowitz-Costa formalism for calculating the effect of ternary G-protein complex model below. The model provides the link between the agonist-receptor-Gprotein ternary complex model (upper panel) and the antagonist binding model (lower panel).
When the binding of the radioligand is inhibited by competition from a single other ligand, itself at steady state, Eq. 13 is recognized as a special case of a more general equation derived by Gaddum (1937) for receptors and Dixon (1953) for enzymes,
where
where (I) is the time constant of the inhibited binding. The symbols C I and K I represent the steady-state and half-inhibition concentrations of the inhibitor, respectively. When the binding of the radioligand is inhibited by competition from n other ligands at steady state, Eq. 13 is further extended to,
where, again, the symbols C i and K i represent the steadystate and half-inhibition concentrations of the individual inhibitors, respectively. As realized by Woolf (Haldane and Stern, 1932; Haldane, 1957) and later by Wong and Hanes (1962) , this equation can be linearized to include any number of competitors at any concentration,
where (0) ‫ס‬ 1/k 3 is the time constant of undirectional binding of the tracer radioligand in the absence of competitors of any kind. The symbols l through n represent the individual ratios between n inhibitors and their inhibitory constants. The equation is the multilinear (n + 1) dimensional Woolf-Wong-Hanes plot (Haldane and Stern, 1932; Haldane, 1957; Wong and Hanes, 1962) The Woolf-Wong-Hanes plot has been recognized as a particularly robust and stable linearization of the Michaelis-Menten equation, which is less sensitive to outliers than other linearizations such as the Eadie-HofsteeScatchard and Lineweaver-Burke plots (Keightley and Cressie, 1980; Keightley et al., 1983) . Also, unlike the linearization of the Michaelis-Menten equation used in enzyme kinetics, no lumping of dependent and independent variables occurs when Eq. 19 is applied to receptor binding . For these reasons, Wong et al. (1986a) 
Single inhibitor
The following treatment validates Eqs. 1 and 2 for the case of a single exogenous competitor: If the exogenous inhibitor is in fact the only competitor of the binding, Eq. 18 reduces to Eq. 16,
A. GJEDDE AND D. F. WONG 990 where (0) ‫ס‬ 1/k 3 . The magnitude of the slope of the dependent variable (I) as a function of the independent variable C I equals V d /(k a K I B max ). When the steady-state concentration of the exogenous inhibitor is measured in blood plasma, the slope also depends on the steady-state ratio between the concentration in blood plasma and the aqueous concentration in the fluid compartments of the brain,
where C I(pl) is the plasma concentration of the inhibitor and f I(pl) is the steady-state ratio of inhibitor concentrations in plasma water and blood plasma, equal to the "free" fraction. For inhibitor concentrations measured in blood plasma, the slope of Eq. 20 is a lumped constant equal to f I(pl) V d /(k a K I ) . The ordinate intercept is V d /(k a B max ), and the abscissa intercept is −K I /f I(pl) . For a single inhibitor, the plasma IC 50 equals the inhibitor's Michaelis constant or plasma half-inhibition concentration K I /f I(pl) , symbolized by K I (pl). When only two measurements are available, the magnitude of K I(pl) can be determined directly from the increase of the time constant of unidirectional binding, relative to its baseline value in the absence of the exogenous inhibitor,
The quantity of exogenous inhibitor bound to the receptors at steady state is the equilibrium solution to the binding equation of an inhibitor,
Because the degree of occupancy of the inhibitor is defined as B I /B max , the occupancy can be calculated from Eqs. 21 and 22 as,
from which Eq. 5 follows.
Multiple competitors
The following treatment validates Eqs. 1 and 2 for the case of multiple competitors. In principle, inhibition by a single competitor is a special case of simultaneous inhibition by multiple competitors. The kinetic treatment of the case of multiple competitors can be used to make inferences about endogenous competitors that cannot otherwise be measured directly. In the presence of n endogenous competitors at steady state, an exogenous (n + 1)st inhibitor causes the time constant of unidirectional binding of the radioligand to increase according to Eq. 18,
where f I(pl) C I(pl) / K I ‫ס‬ C n+I / K n+I ‫ס‬ C I / K I ‫ס‬ I . The ordinate intercept is (n) and the absolute value of the negative abscissa intercept is the plasma IC 50 of the administered exogenous inhibitor with the steady-state plasma concentration C 1(pl) ,
In the absence of the exogenous (n + I)st inhibitor, the sum of the concentrations of the endogenous n competitors, relative to their inhibitory constants ( x ‫ס‬ ∑ n i‫1ס‬ i ), is,
In the presence of the (n − 1) other endogenous competitors, the equilibrium binding of any competing agonist with a concentration C a obeys the equation,
The steady-state saturation together accomplished by the n endogenous competitors ( x ‫ס‬ ⌺ n i‫1ס‬ i ) is ⌺ n i‫1ס‬ B i / B max such that, in the absence of the exogenous (n + I)st inhibitor,
from which Eq. 3 follows. The occupancy of the exogenous (n + 1)st inhibitor ( I ) is B I / B max such that its occupancy of the receptors is,
from which Eq. 6 follows.
Multiple competitors and elevated binding capacity
The following treatment validates Eqs. 1 or 2 for the cases in which the maximum receptor binding capacity may change. Validation is necessary because Eq. 23 assumes that the value of B max is constant. However, if a
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change of B max to, say, B + max is physiologically or pathologically linked to, or coincidentally associated with, the release of one or more endogenous competitors, the value of the time constant of unidirectional binding must change accordingly,
where B + max is the binding capacity that coexists with the n competitors. It follows that,
. Thus, at steady state, the slope of the linear relation expressed in Eq. 32, correctly reflects the binding capacity, regardless of the presence of endogenous competitors.
2 The abscissa intercept of Eq. 32 correctly reflects the IC 50 of the administered inhibitor under the influence of the endogenous competitors, whether or not they exist or are known,
Therefore, the estimations of the elevated B + max and the plasma IC 50 of the exogenous inhibitor are independent, such that the estimate of the IC 50 will not be biased by a change of B max . The sum of the concentrations of the endogenous competitors, relative to their individual inhibitory constants, must be corrected for the change of B max to B + max . This sum can be calculated from the relation,
According to Eq. 24, the total receptor occupancy of the endogenous competitors is unaffected by the elevation to B + max .
from which Eq. 3 follows.
G-Protein action
The response to G-protein-mediated neurotransmission is generally believed to be proportional to the quantity of ternary agonist-receptor-G-protein complexes (Burstein et al., 1997) , as defined by DeLean et al. (1980) and Samama et al. (1993) . The affinity of G-proteincoupled receptors for the activating agonist is low when the receptor is dissociated from its G-protein and high on interaction with the GTP-free form of the protein (GTPshift) ). This property of G-proteincoupled agonist binding sites affects the interpretation of studies of dopamine release and can be modeled by means of an extension of Eq. 28. The extension was suggested by the original ternary complex model of del Castillo and Katz (1957) , according to which the quantity of bound agonist can be expressed as,
where the subscript "a" refers to the specific agonist, the term B a refers to the amount of the receptor-agonist complex that is not coupled to G-protein, K a refers to the basal affinity to the agonist, and KЈ a refers to the apparent receptor affinity as modified by G-protein binding,
where C g is the G-protein concentration and K g the receptor affinity to the G-proteins. These equations show that Eq. 18 is also valid for the case of G-protein modulation of receptor affinity to the agonist. From the equations follow the equation for the steady-state receptoragonist-G-protein complex itself,
where B ag is the ternary G-protein complex, and C g is the concentration of the G-protein that is not part of a ternary complex, such that C g ‫ס‬ (G max − B ag )/V d . The combined number of receptors occupied by the agonist is therefore,
In the absence of other putative endogenous competitors, this equation expresses the simple interaction of the agonist and G-protein concentrations in determining the quantity of the agonist-receptor-G-protein complexes,
where B ag also indicates the number of receptors responsible for the effect of the receptor occupancy. This quantity-that is, the ternary receptor-agonist-G-protein complexes-depends on the concentration of the agonist, the total quantities of receptor and G-protein, B max and G max , and the affinity of the receptors to the G-protein. As C g must decline when G-protein associates with the receptor protein, the total quantity of the ternary complexes (B ag ) can be calculated by replacing the term C g with the terms for the variables of which it is a function (V d C g ‫ס‬ G max − B ag ). Equation 39 shows that the apparent halfsaturation concentration of the agonist in the elicitation of an effect may be much greater than indicated by the intrinsic affinity constant of the receptors toward the agonist (K a ). 3 This difference between the simple affinity of the receptors to the agonist and the concentration that elicits a half-maximum effect may explain the characteristic GTP-shift or increase of agonist affinity in vivo that makes it difficult to predict the absolute concentration of the agonist associated with an observed effect.
Agonist release
In the section above, Eq. 31 was derived under the assumption that the concentrations of endogenous competitors do not change when the exogenous inhibitor is administered. However, if the administration of the exogenous inhibitor is associated with release of the endogenous competitors, the value of the binding time constant changes from Ј to Љ in Eq. 26,
where ⌬C a represents the additional release of agonist, such that, 
where ‫ס‬ (⌬C a րK a )ր(C I(pl) րK I(pl) ) and ⌫ ‫ס‬ K a /KЈ a . Together, these formulae shrink to
where Љ(0) ‫ס‬ (0)(1 + ) B max /B + max . This is the equation underlying Eq. 1 such that ‫ס‬ Љ(n) and (I) ‫ס‬ Љ(n + I). The measured or calculated half-inhibition plasma concentration constant IC 50 (symbolized by K IC50(pl) ) is defined as
where i is the nonagonist inhibitor sum ⌺ n−1 i‫1ס‬ C i / K i , ⌫ is the ratio K a /KЈ a (see Eq. 37), equal to the relative increase of the average agonist affinity because of Gprotein binding to the occupied receptors, and a is the agonist ratio C a /K a . The formula shows that the ability of an antagonist or agonist to inhibit the binding of a radioligand depends on several factors that are difficult or impossible to monitor, including the local hematocrit of the cerebral vascular bed, which may change as a function of blood flow, and the local G-protein environment of the receptors, which may change as a function of interventional effects not directly related to a change of agonist concentration.
